From reaction to prevention: rethinking vocal fold paralysis after thyroid surgery

Perspective

Unilateral vocal fold paralysis after thyroid and parathyroid surgery remains a complication of disproportionate clinical impact. Even when transient, recurrent laryngeal nerve (RLN) injury may result in dysphonia, dysphagia, impaired cough, aspiration risk, and measurable deterioration in quality of life. Permanent injury carries durable functional and psychosocial consequences that extend well beyond the perioperative period. Despite sustained refinement in endocrine surgical technique, RLN palsy continues to occur at rates that are clinically meaningful and, for many patients, life-altering.

In this context, Carvajal-Alegria and colleagues report a randomized, double-blind, placebo-controlled trial evaluating a short course of oral corticosteroids for unilateral vocal fold paralysis following thyroidectomy or parathyroid surgery (1). Their findings are clear: oral corticosteroids did not improve early vocal fold remobilization, voice quality, or functional outcomes compared with placebo. Speech therapy remained the principal determinant of recovery. This is a valuable negative trial. It addresses a common, often empirical postoperative practice and replaces uncertainty with evidence.

Interpreting the findings

The appeal of corticosteroids in this setting is intuitive. Postoperative vocal fold immobility is frequently presumed to reflect inflammatory neurapraxia, and steroids are familiar, accessible, and theoretically aligned with edema reduction. The biology of RLN injury, nonetheless, is rarely so singular. Traction, compression, ischemia, and thermal spread often coexist and occur at the decisive moment of dissection. The trial’s results are therefore biologically coherent. While postoperative therapy may influence symptom burden, it operates downstream of the inciting injury. The absence of a meaningful treatment effect should not be interpreted as failure of the intervention, but as a reflection of neurophysiology. Once RLN injury has occurred, the capacity for pharmacologic rescue is inherently limited (1).

Methodologically, predictable concerns regarding sample size and statistical power are appropriately addressed. Only a subset of patients developed postoperative vocal fold paralysis and met criteria for randomization, reflecting the epidemiology of the complication rather than a design flaw. Importantly, the absence of even a directional signal favoring corticosteroids across remobilization and voice metrics strengthens confidence in the conclusion.

The structural limits of postoperative rescue

The broader implication of this trial extends beyond medication choice. It highlights the structural limits of postoperative intervention for nerve injury. Edema and inflammation are frequently secondary phenomena, not primary drivers of dysfunction. Even neurapraxia reflects structural and metabolic disturbance that cannot be reliably reversed once established. Postoperative care remains essential for rehabilitation, symptom management, and patient counseling. Its role, however, is necessarily secondary. It addresses consequences rather than causes. For surgeons, this distinction matters. If postoperative therapies offer limited leverage, the dominant opportunity for improvement lies upstream.

Within this framework, it is useful to consider how structural constraints can also affect technically oriented postoperative interventions. Injection laryngoplasty after thyroid surgery can alleviate symptoms associated with unilateral vocal fold paralysis, yet the procedure is frequently technically challenging in this setting. Extensive dissection and fibrotic healing often obscure the cricothyroid membrane, making trans-cricothyroid access technically challenging. Recognition that edema and inflammation are often secondary phenomena further delineates that procedural difficulty is frequently structural rather than inflammatory in origin.

A recent study demonstrates a practical strategy to address this limitation by using pre-procedural ultrasound to mark the cricothyroid membrane at the skin surface immediately prior to injection. This method improved procedural accuracy compared with reliance on palpation alone, reduced procedure time, and was associated with improved voice outcomes and patient satisfaction. Inclusion of this evidence provides a balanced perspective, where pharmacologic rescue may be limited once injury is established, but technical adaptations can mitigate structural barriers encountered during postoperative management (2).

Reframing prevention

The evolution of thyroid surgery has consistently followed a single trajectory. Improved anatomical understanding enables improved visualization, which in turn reduces complications. Direct RLN identification before gland resection remains the accepted and sought out standard of care. Nevertheless, this standard is challenged by anatomical variability, inflammatory distortion, reoperative fields, surgical dexterity, and the small caliber of neural anatomy.

The identification and preservation of neural structures remain persistent in challenges across surgical disciplines, as intraoperative nerve injury continues to represent a major source of postoperative morbidity. Over the past decades, several strategies have been developed to support intraoperative nerve assessment, with intraoperative neuromonitoring emerging as the most widely adopted adjunctive tool.

Intraoperative neuromonitoring provides functional information through electrical stimulation and electromyographic recording, offering real-time feedback during critical surgical maneuvers and the ability to alert the surgeon to changes in motor nerve function. Despite these advantages, neuromonitoring presents recognized limitations. Signal reliability can potentially be affected by anesthetic agents, electrode positioning, patient-specific anatomy, and equipment-related factors, resulting in false-negative or false-positive findings. From a biological perspective, neuromonitoring predominantly evaluates motor pathways, while sensory and autonomic fibers are neither reliably nor readily assessed. Notably, neuromonitoring does not provide direct anatomical visualization of neural structures, but rather indirect functional information that unequivocally requires interpretation within the operative field.

These limitations have motivated interest in complementary strategies capable of providing direct, real-time nerve visualization. The concept of visualizing nerves in an intuitive, anatomy-based manner, analogous to visualization of vascular or biliary structures, has long been proposed to reduce inadvertent nerve manipulation at the point of highest risk. Historically, optical nerve identification strategies focused on exogenous fluorescent contrast agents designed to bind neural tissue. While these agents demonstrated proof of concept, their clinical translation has been constrained by concerns related to safety, pharmacokinetics, off-target binding, and regulatory scrutiny. In response, research efforts have increasingly focused on contrast-free fluorescence imaging. Neural auto-fluorescence represents one such approach. By exploiting intrinsic optical properties of neural tissue under near ultraviolet excitation, autofluorescence enables real-time nerve visualization without dyes, contrast agents, or nocive electrical stimulation.

Implementing safe, non-ionizing wavelengths in combination with specialized optical filters, intrinsic fluorescent signals from neural tissue can be captured and displayed in real time without altering standard surgical workflow. Thyroidectomy series have demonstrated that the RLN emits a distinct auto-fluorescent signal that can be differentiated from surrounding tissues with high sensitivity and specificity, often before formal nerve exposure (3,4). Earlier identification allows surgeons to plan dissection trajectories proactively, potentially reducing unnecessary manipulation, traction, and thermal exposure. In this context, visualization is not an adjunct to nerve preservation, but a mechanistic strategy for risk reduction.

Context beyond thyroid surgery

The principle of prevention through enhanced visualization is not anatomically confined. Across multiple surgical domains, improved nerve identification has been associated with functional preservation. In breast surgery, auto-fluorescence guided identification of intercostal sensory nerves has been associated with preservation of postoperative sensation (5,6). In open inguinal hernia repair, feasibility studies describe reliable intraoperative identification of key inguinal nerves with favorable early functional outcomes (7,8). Comparable applications have been reported in parotidectomy and prostatectomy, where nerve preservation is central to postoperative function (9,10). In these settings, fluorescence-based visualization has demonstrated improved nerve identification relative to conventional white light imaging, supporting its role as a preventive adjunct rather than a reactive measure. These data are heterogeneous and exploratory and should not be overextended. Nevertheless, their consistency across anatomical regions supports biological plausibility and reinforces the prevention of first logic underscored by the discussed steroid trial.

Future directives

If visualization-based prevention is the proposed path forward, the evidentiary bar is clear. Detection accuracy must translate into meaningful reductions in RLN palsy and improved patient-reported voice outcomes. Comparative effectiveness studies against contemporary best practices, including meticulous dissection and selective neuromonitoring, will be essential. Implementation factors, including workflow integration, cost considerations, and the risk of false reassurance, must also be addressed.

Conclusions

Carvajal Alegria and colleagues provide a clear answer to a common postoperative question. Routine oral corticosteroids do not improve remobilization or voice outcomes after post-thyroidectomy vocal fold paralysis (1). The importance of this trial lies not only in what it discourages, but in what it clarifies: the future of RLN preservation is unlikely to be pharmacologic. It is more likely to be preventive and visual. If meaningful reductions in vocal fold paralysis are the goal, the path forward is consistent with the evolution of thyroid surgery itself. Early neural identification, reduced manipulation, and recognition that postoperative therapy cannot substitute for intraoperative insight.

Acknowledgments

None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Gland Surgery. The article has undergone external peer review.

Peer Review File: Available at https://gs.amegroups.com/article/view/10.21037/gs-2026-1-0011/prf

Funding: None.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://gs.amegroups.com/article/view/10.21037/gs-2026-1-0011/coif). R.A. reports research grants from Abiomed and Johnson & Johnson MedTech, patent inventorship for S.P.A.R.K. Model software, leadership roles in ASAIO and ISFGS, and stock ownership in Dendrite Imaging. F.D., A.R. and R.J.R. report leadership roles in ISFGS, and stock ownership in Dendrite Imaging. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Carvajal-Alegria E, Girault N, Donatini G, et al. Oral Corticosteroids in Vocal Fold Paralysis After Thyroid Surgery: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg 2025;151:874-80. [Crossref] [PubMed]
2. Park J, Kim MS. Comparison of Injection Laryngoplasty With and Without Ultrasound Marking After Thyroid Surgery. J Voice 2025; [Crossref]
3. Dip F, Aleman R, Dip HR, et al. Enhancing Recurrent Laryngeal Nerve Detection with Neural Autofluorescence in Thyroid Surgery. J Am Coll Surg 2025; [Crossref]
4. Dip F, Falco J, White K, et al. Fluorescence imaging to visualize the recurrent laryngeal nerve during thyroidectomy procedures: analysis of 65 cases and 81 nerves. Surg Endosc 2024;38:1406-13. [Crossref] [PubMed]
5. Rancati AO, Angrigiani C, Nahabedian MY, et al. Fluorescence Imaging to Identify and Preserve Fifth Intercostal Sensory Nerves during Bilateral Nipple-sparing Mastectomies. Plast Reconstr Surg Glob Open 2023;11:e5048. [Crossref] [PubMed]
6. Ramírez MF, Nahabedian MY, Santos HM, et al. Intraoperative Fluorescence Imaging to Identify and Preserve the Fifth Anterior Intercostal Sensory Nerves during Inferior Pedicle Reduction Mammoplasty. Plast Reconstr Surg Glob Open 2024;12:e5699. [Crossref] [PubMed]
7. Harraca J, Aleman R, Schor M, et al. Introducing autofluorescence technology for inguinal nerve visualization in open anterior hernia surgery: a step forward in surgical precision and safety. Hernia 2025;29:295. [Crossref] [PubMed]
8. Dip F, Harraca JL, Rancati A, et al. Fluorescence-guided inguinal hernia repair with heightened nerve visualization to prevent chronic post-operative inguinal pain: Case report. Int J Surg Case Rep 2025;127:110911. [Crossref] [PubMed]
9. Dip F, Aleman R, Rancati A, et al. Nerve-Sparing Parotidectomy Guided by Nerve Auto-Fluorescence Technology. Cureus 2025;17:e77025. [Crossref] [PubMed]
10. Degiovanni R, Zabala G, Degiovanni D, et al. Case report: Fluorescence-guided laparotomic radical prostatectomy with heightened nerve visualization. Int J Surg Case Rep 2024;120:109820. [Crossref] [PubMed]